Last reviewed · How we verify
APH-1501
APH-1501 is a cannabinoid-based therapy.
APH-1501 is a cannabinoid-based therapy. Used for Treatment-resistant epilepsy.
At a glance
| Generic name | APH-1501 |
|---|---|
| Sponsor | Aphios |
| Drug class | cannabinoid |
| Target | CB1/CB2 receptors |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
It is being investigated for its potential therapeutic effects through interaction with the endocannabinoid system. The exact mechanism of action is not well understood at this time.
Approved indications
- Treatment-resistant epilepsy
Common side effects
- Dizziness
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APH-1501 CI brief — competitive landscape report
- APH-1501 updates RSS · CI watch RSS
- Aphios portfolio CI